Phase III CRUISE 2 study of SFP success for Iron Deficiency
Rockwell Medical reported top-line results from the long-term CRUISE-2 Phase III efficacy study of SFP. SFP is the Company's late-stage investigational iron-delivery drug for the treatment of Iron Deficiency in Chronic Kidney Disease patients receiving haemodialysis.
In this study, SFP met the primary endpoint, demonstrating a statistically significant mean change in haemoglobin from baseline to End-of-Treatment. Additionally, SFP met key secondary endpoints, including maintenance of haemoglobin, maintenance of reticulocyte haemoglobin, and increase in serum iron pre-to-post treatment without an increase in ferritin. This long-term study is the second and final study of two identical Phase III efficacy studies to provide clinical data required for the Company to file a New Drug Application (NDA) with the FDA.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins